Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience

Clinical Colorectal Cancer
Vittorio GebbiaCarlo Barone

Abstract

This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as third- or fourth-line therapy in a retrospective series of patients with metastatic colorectal cancer refractory to oxaliplatin and irinotecan. Most patients (90%) had been previously treated with adjuvant 5-fluorouracil/leucovorin, and all had received oxaliplatin-based regimens before receiving irinotecan-based second-line treatment. Sixty patients with irinotecan-refractory colorectal cancer received a regimen comprising weekly irinotecan 120 mg/m2 as a 1-hour intravenous infusion and cetuximab 400 mg/m2 infused over 2 hours as the initial dose and 250 mg/m2 infused over 1 hour for the subsequent administrations. A single treatment cycle comprised 4 weekly infusions followed by 2 weeks of rest. According to an intent-to-treat analysis, a partial response was exhibited in 12 of 60 enrolled patients (20%; 95% confidence interval, 11%-32%) with a median duration of 5.1 months (range, 3-7.4 months). The tumor growth control rate was 50% (95% confidence interval, 37%-63%). Objective responses did not correlate with performance status, number of sites of disease, and pretreatments or epidermal growth factor receptor status. The medi...Continue Reading

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Mar 16, 1994·Journal of the National Cancer Institute·D AbigergesD Gandia
Apr 21, 1994·The New England Journal of Medicine·C G Moertel
Feb 15, 2001·International Journal of Radiation Oncology, Biology, Physics·P M Harari, S M Huang
Jun 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DucreuxU Vanhoefer
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lee M Ellis, Paulo M Hoff
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Jan 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ki Young ChungLeonard B Saltz
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel VallböhmerHeinz-Josef Lenz
Jul 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hanna Kelly, Richard M Goldberg

❮ Previous
Next ❯

Citations

Aug 18, 2009·Journal of Experimental & Clinical Cancer Research : CR·Jeffrey B HoagMark E Lund
Dec 18, 2012·Immunotherapy·José Medina-Echeverz, Pedro Berraondo
Oct 27, 2006·Expert Opinion on Emerging Drugs·Bruno VincenziGiuseppe Tonini
Nov 6, 2007·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·D A WichertsR Adam
Feb 17, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D ArnoldJ Taieb
Feb 16, 2018·Integrative Cancer Therapies·Friedemann SchadMegan L Steele
Sep 6, 2007·Cancer Chemotherapy and Pharmacology·M G GundgaardE Ehrnrooth
Aug 17, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Jesús García-Foncillas, Eduardo Díaz-Rubio
Mar 15, 2011·Oncotarget·Rajeev S Samant, Lalita A Shevde

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.